Damora Therapeutics (DMRA) Change in Account Payables (2019 - 2026)
Damora Therapeutics (DMRA) reported Change in Account Payables of $375000.0 for Q1 2026, up 1730.43% on a YoY basis from $20486.9 in Q1 2025, and up 507.61% quarter-over-quarter from -$92000.0 in Q4 2025.
Damora Therapeutics (DMRA) Change in Account Payables (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at $375000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 1730.43% year-over-year to $375000.0; the trailing twelve-month figure through Mar 2026 stood at $449000.0 (up 134.25% YoY), and the FY2025 full-year result was $51000.0, up 103.85% from the prior year.
- Change in Account Payables for Q1 2026 stood at $375000.0, up from -$92000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.0 million in Q2 2023, with the low at -$2.8 million in Q4 2023.
- Historically, Change in Account Payables has averaged -$42823.5 across 5 years, with a median of -$92000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 329.87% — and 2026, when it soared 1730.43%.
- Damora Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then plunged by 292.31% to -$2.8 million in 2023, then jumped by 95.46% to -$126000.0 in 2024, then gained by 26.98% to -$92000.0 in 2025, then surged by 507.61% to $375000.0 in 2026.
- The last three Change in Account Payables figures came in at $375000.0 (Q1 2026), -$92000.0 (Q4 2025), and -$236000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | 375,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 375,000.00 |
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -2.78 Mn |
| Dec 31, 2023 | -2.78 Mn |